Suppr超能文献

经导管二尖瓣介入治疗(TRAMI)注册研究:重度左心室射血分数降低患者应用 MitraClip™ 治疗的安全性和有效性。

Safety and efficacy of MitraClip™ therapy in patients with severely impaired left ventricular ejection fraction: results from the German transcatheter mitral valve interventions (TRAMI) registry.

机构信息

Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany.

Department of Cardiology and Pneumology, University of Göttingen, Göttingen, Germany.

出版信息

Eur J Heart Fail. 2018 Mar;20(3):598-608. doi: 10.1002/ejhf.910. Epub 2017 Aug 18.

Abstract

AIMS

The aim of the present study was to assess the safety and efficacy of percutaneous mitral valve repair using the MitraClip™ device in patients with severely reduced systolic left ventricular (LV) function.

METHODS AND RESULTS

Among 777 MitraClip™ implantations included in the German mitral valve registry, we identified 256 patients suffering from severely reduced LV function [ejection fraction (EF) <30%] in whom successful percutaneous mitral valve repair was performed. Procedural safety, efficacy, and 1-year outcome was compared with 241 patients with preserved LV function (EF >50%) and 280 patients presenting with an EF 30-50% prior to MitraClip™ therapy. High procedural success rates, low periprocedural complication rates, and low residual mitral regurgitation grades at discharge were achieved throughout all groups. In-hospital mortality was low and comparable in all groups. After 1 year, mortality rates were 24.2% (EF <30%), 17.3% (EF 30-50%), and 18.9% (EF >50%). Major adverse cardiac or cardiovascular event rates were 29.7% (EF <30%), 24.4% (EF 30-50%), and 23.5% (EF >50%). Procedural failure was the main predictor for mortality in EF <30% patients (hazard ratio 10.38; 95% CI 3.71-29.02). Improved clinical symptoms were observed in the majority of patients in all groups. Thus, 69.5% of EF <30% patients improved by one or more New York Heart Association functional class. Compared with patients with preserved LV function, this is a significantly larger proportion (EF >50%: 56.8%; P < 0.05). Moreover, quality of life, being very poor at baseline, improved distinctively in severe heart failure patients.

CONCLUSION

In patients with severely reduced systolic LV function undergoing MitraClip™ therapy, procedural safety, efficacy, and clinical improvement after 1 year are comparable to patients with preserved LV function.

摘要

目的

本研究旨在评估经皮二尖瓣修复术(MitralClip™ 装置)治疗严重左心室收缩功能障碍(左心室射血分数 <30%)患者的安全性和疗效。

方法和结果

在德国二尖瓣注册中心纳入的 777 例 MitraClip™ 植入患者中,我们确定了 256 例左心室收缩功能严重降低(左心室射血分数 <30%)的患者,这些患者成功进行了经皮二尖瓣修复术。比较了各组间的手术安全性、疗效和 1 年结果,这些组包括 241 例左心室射血分数保留(>50%)患者、280 例术前左心室射血分数 30-50%的患者。所有组均达到了较高的手术成功率、较低的围手术期并发症发生率和较低的出院时残余二尖瓣反流程度。住院死亡率低且各组之间相似。1 年后,死亡率分别为 24.2%(EF <30%)、17.3%(EF 30-50%)和 18.9%(EF >50%)。主要不良心脏或心血管事件发生率分别为 29.7%(EF <30%)、24.4%(EF 30-50%)和 23.5%(EF >50%)。手术失败是 EF <30%患者死亡的主要预测因素(风险比 10.38;95%CI 3.71-29.02)。所有组中大多数患者的临床症状均有改善。因此,69.5%的 EF <30%患者的纽约心脏协会功能分级提高了一个或多个级别。与射血分数保留的患者相比,这是一个显著更大的比例(EF >50%:56.8%;P < 0.05)。此外,基线时生活质量极差的严重心力衰竭患者明显改善。

结论

在接受 MitraClip™ 治疗的严重左心室收缩功能障碍患者中,手术安全性、疗效和 1 年后的临床改善与射血分数保留的患者相当。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验